Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.01 USD
-0.20 (-2.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.02 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Theravance Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 57 | 51 | 55 | 72 | 73 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 57 | 51 | 55 | 72 | 73 |
Selling & Adminstrative & Depr. & Amort Expenses | 113 | 143 | 313 | 370 | 325 |
Income After Depreciation & Amortization | -56 | -92 | -258 | -298 | -252 |
Non-Operating Income | 9 | 6 | 105 | 56 | 42 |
Interest Expense | 2 | 6 | 47 | 45 | 32 |
Pretax Income | -49 | -93 | -200 | -287 | -242 |
Income Taxes | 6 | 0 | 0 | -9 | -5 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -55 | -93 | -199 | -278 | -236 |
Extras & Discontinued Operations | 0 | 965 | 0 | 0 | 0 |
Net Income (GAAP) | -55 | 872 | -199 | -278 | -236 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -56 | -89 | -252 | -292 | -249 |
Depreciation & Amortization (Cash Flow) | 0 | 3 | 6 | 6 | 3 |
Income After Depreciation & Amortization | -56 | -92 | -258 | -298 | -252 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 55.30 | 73.59 | 69.46 | 62.35 | 55.61 |
Diluted EPS Before Non-Recurring Items | -1.00 | -1.26 | -2.87 | -4.20 | -4.25 |
Diluted Net EPS (GAAP) | -1.00 | 11.85 | -2.87 | -4.46 | -4.25 |
Fiscal Year end for Theravance Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 14.26 | 14.50 | 17.57 | 15.69 | 13.75 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 14.26 | 14.50 | 17.57 | 15.69 | 13.75 |
SG&A, R&D, and Dept/Amort Expenses | 29.96 | 25.71 | 23.80 | 24.45 | 29.88 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.70 | -11.21 | -6.23 | -8.76 | -16.13 |
Non-Operating Income | 1.13 | 1.43 | 1.85 | 1.79 | 2.50 |
Interest Expense | 0.64 | 0.63 | 0.62 | 0.61 | 0.57 |
Pretax Income | -15.22 | -10.40 | -5.02 | -7.58 | -14.19 |
Income Taxes | 1.31 | 1.26 | 3.49 | 1.37 | 1.46 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -16.53 | -11.66 | -8.51 | -8.95 | -15.65 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -16.53 | -11.66 | -8.51 | -8.95 | -15.65 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 48.75 | 48.28 | 49.42 | 52.36 | 56.68 |
Diluted EPS Before Non-Recurring Items | -0.34 | -0.24 | -0.17 | -0.17 | -0.28 |
Diluted Net EPS (GAAP) | -0.34 | -0.24 | -0.20 | -0.17 | -0.28 |